BMC Neurology (Jul 2021)

Clinical features and outcome of Guillain–Barre syndrome in Saudi Arabia: a multicenter, retrospective study

  • Mohammed H. Alanazy,
  • Sawsan S. Bakry,
  • Afnan Alqahtani,
  • Norah S. AlAkeel,
  • Naael Alazwary,
  • Afag M. Osman,
  • Rania A. Mustafa,
  • Talal M. Al-Harbi,
  • Sameeh O. Abdulmana,
  • Aimee C. Amper,
  • Yousef Aldughaythir,
  • Abdulrahman S. Ali,
  • Seraj Makkawi,
  • Alaa Maglan,
  • Loujen Alamoudi,
  • Feras Alsulaiman,
  • Majed Alabdali,
  • Aysha A. AlShareef,
  • Ahmad R. Abuzinadah,
  • Ahmed K. Bamaga

DOI
https://doi.org/10.1186/s12883-021-02314-5
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background Guillain–Barre syndrome (GBS) is an inflammatory polyradiculoneuropathy characterized by rapidly evolving weakness and areflexia, reaching nadir within 4 weeks. Data on the characteristic of GBS in Saudi Arabia are limited. This study aimed to describe the clinical, electrophysiological, and laboratory characteristics and outcome of a multicenter cohort of patients with GBS. Methods This is a retrospective multicenter nationwide study. Patients who had GBS, identified through Brighton Criteria, between January 2015 and December 2019 were included. Data collected included demographics, clinical features, cerebrospinal fluid profile, reported electrophysiological patterns, treatment, and outcome. Reported GBS subtypes were compared using chi-square, Fisher's exact, or Mann–Whitney U tests, as appropriate. Results A total of 156 patients with GBS were included (men, 61.5%), with a median age of 38 (interquartile range, 26.25–53.5) years. The most commonly reported antecedent illnesses were upper respiratory tract infection (39.1%) and diarrhea (27.8%). All but two patients (98.7%) had weakness, 64.1% had sensory symptoms, 43.1% had facial diplegia, 33.8% had oropharyngeal weakness, 12.4% had ophthalmoplegia, and 26.3% needed mechanical ventilation. Cytoalbuminological dissociation was observed in 69.1% of the patients. GBS-specific therapy was administered in 96.8% of the patients, of whom 88.1% had intravenous immunoglobulin, and 11.9% had plasmapheresis. Approximately half of the patients were able to walk independently within 9 months after discharge, and a third regained the ability to walk independently thereafter. Death of one patient was caused by septicemia. Acute inflammatory demyelinating polyradiculoneuropathy was the most commonly reported GBS subtype (37.7%), followed by acute motor axonal neuropathy (29.5%), and acute motor-sensory axonal neuropathy (19.2%). Conclusion The clinical and laboratory characteristics and outcome of GBS in the Arab population of Saudi Arabia are similar to the international cohorts. The overall prognosis is favorable.

Keywords